

CKDSens

A novel home healthcare platform for chronic kidney disease

Barcelona, 29th September 2020



Adrià Maceira adria.maceira@renalyse.com

CKDSENS CONSORTIUM



Technological partner



Clinical partner



Patient & specialist education partner





Business & Regulatory partner




Manufacturing & Software partner



Living labs partner









To Whom

CKD patients: CREATININE AND POTASSIUM ANALYSES





ACE & ARB drugs increases the risk of arrhythmia by increasing potassium in blood







THE SOLUTION

THE CORE TECHNOLOGY




New paper-based creatinine and potassium sensors

Automated device

Wireless connectivity and user centered design

Seamless doctor to patient interaction










THE SOLUTION - HOME




THE SOLUTION - SOFTWARE




CKDSens













USER CASES

MEDICAL OFFICE



DIALYSIS



RADIOLOGY



HOME CARE









THE PATIENT BENEFITS

Point of Care device

- ✓ No need to wait for the analysis
- ✓ Direct interaction with your doctor with objective information
- ✓ Less painful, as the sample is a drop of blood
- ✓ Same day analysis and visit



Home Care device

- ✓ No need to go to the Hospital for an analysis
- ✓ Tool for better autocontrol of the disease
- ✓ Simple and easy to use device
- ✓ Direct communication channel









THANKS!



Adrià Maceira adria.maceira@renalyse.com

